08:13 AM EDT, 03/16/2026 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Monday it has entered a clinical supply agreement with Johnson & Johnson ( JNJ ) to evaluate investigational drug MRT-2359 in combination with Erleada in patients with metastatic castration-resistant prostate cancer with androgen receptor mutations.

Under the agreement, Monte Rosa Therapeutics ( GLUE ) will sponsor and conduct the trial while Johnson & Johnson ( JNJ ) will provide Erleada, the company said.

Monte Rosa Therapeutics ( GLUE ) said it plans to initiate a phase 2 study in Q3 to assess the drug combination.

The planned study will enroll up to 25 patients and will evaluate measures including PSA response, RECIST response, duration of response, progression-free survival and safety, the company said.

Financial terms were not disclosed.